Ethical Compliance Statement: No IRB permission required (this is a Clinical Vignette). Declaration of patient consent: Informed patient consent was provided from the mother, in compliance with local laws regarding patient authorizations relating to the use or disclosure of protected health information and the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and with journal requirements at Author Guidelines-Movement Disorders Clinical Practice-Wiley Online Library. The signed consent is on file. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflict of Interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work. Financial Disclosures for the Previous 12 Months: AJC reports no disclosures. DLG has received has research grant funding from the NIH and the DOD. He has received salary compensation through Cincinnati Children's for work as a clinical trial site investigator from Emalex Biosciences, Inc. (clinical trial, Tourette's Syndrome), PTC Therapeutics (registry and clinical trial, Amino Acid Decarboxylase Deficiency), Neurocrine Biosciences (clinical trial, cerebral palsy), and Quince Therapeutics (clinical trial, ataxia telangiectasia). He has received compensation for expert testimony for the U.S. National Vaccine Injury Compensation Program, through the Department of Health and Human Services. He has received payment for medical expert opinions through TeladocHealth International. He has served as a paid consultant for PTC Therapeutics, Noema Pharma, and Emalex Biosciences and has received travel support to attend investigator meetings. He has provided educational lectures for Illumina, Inc and PTC Therapeutics, Inc. He has received book/publication royalties from Elsevier and Wolters Kluwer. BEH reports no disclosures. JM reports no disclosures. AJE has received grant support from the NIH and the Michael J. Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, Bial, Kyowa Kirin, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies” and cofounded REGAIN Therapeutics to fund preclinical studies. He has relinquished his right to any personal income from future treatments. Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Data S1. ICMJE MDCP 6056932. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Chirigos et al. (Tue,) studied this question.